dievini quits selling CureVac’s common shares to the public
February 22, 2022dievini Hopp BioTech holding GmbH & Co. KG (dievini), DH-LT-Investments GmbH and Dietmar Hopp, as well as the managing directors of dievini, have announced that they no longer plan to sell some of the CureVac common shares (Nasdaq: CVAC) to the public, as reported in a 13-D filing with the U.S. Securities and Exchange Commission (SEC) on 13 January 2022.
The parties have today made a 13-D filing with the SEC indicating this change and stating that they may make additional private transfers amongst themselves, the company said.
Dietmar Hopp commented: “We have been invested in CureVac since 2005 and strongly believe in the Company’s potential and the future of their mRNA technology. We remain committed to the CureVac strategy and team which, together with its partners, is working hard to bring novel treatments to patients with infectious diseases or cancer.”